Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab.

Elisabeth Sophie BergenAmelie BinterAngelika Martina StarzerGerwin HellerBarbara KieselKristina Tendl-SchulzZsuzsanna Bago-HorvathJulia FurtnerJohannes LeitnerRuth ExnerFlorian FitzalKarin DieckmannGeorg WidhalmMatthias PreusserAnna Sophie BerghoffRupert Bartsch

Published in: Therapeutic advances in medical oncology (2021)

First-line therapy with dual HER2-inhibition of TP after BM diagnosis was associated with the longest median OS times in patients with BCBM.

Keyphrases

brain metastases
small cell lung cancer
epidermal growth factor receptor
metastatic breast cancer
bone marrow
cell therapy
replacement therapy